Clinical trialNCT01286740CompletedPhase 2Interventional

Study to Evaluate Switching From a Regimen Consisting of the Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (STR) to the Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate STR

SponsorGilead SciencesEnrollment50HIV-1 Infection

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this Phase 2b study was to evaluate the efficacy and safety of the emtricitabine/rilpivirine/tenofovir disoproxil fumarate (FTC/RPV/TDF) STR, after switching from the efavirenz (EFV)/FTC/TDF STR at baseline, in maintaining HIV-1 RNA \< 50 copies/mL at Week 12. HIV-infected patients were enrolled if they had received EFV/FTC/TDF for ≥ 3 months prior to study start, were experiencing safety or tolerability concerns (in particular, EFV-related intolerance), and wished to change to an alternate, better-tolerated regimen.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

David Pugatch, MD
Gilead Sciences
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

18 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Living Hope Clinical Foundation
Long Beach, California, United States
Anthony Mills Md, Inc.
Los Angeles, California, United States
Peter J. Ruane Md Inc
Los Angeles, California, United States
la Playa Medical Group and Clinical Research
San Diego, California, United States
Capital Medical Associates, Pc
Washington D.C., District of Columbia, United States
Dupont Circle Physicians Group, P.C.
Washington D.C., District of Columbia, United States
Whitman Walker Clinic
Washington D.C., District of Columbia, United States
the Kinder Medical Group
Miami, Florida, United States
Orlando Immunology Center
Orlando, Florida, United States
Atlanta Id Group
Atlanta, Georgia, United States
Infectious Disease Specialists of Atlanta
Decatur, Georgia, United States
Northstar Medical Center
Chicago, Illinois, United States
Community Research Initiative of New England
Boston, Massachusetts, United States
Be Well Medical Center, P.C.
Berkley, Michigan, United States
Southampton Healthcare, Inc.
St Louis, Missouri, United States
Southwest Infectious Disease Clinical Research, Inc.
Addison, Texas, United States
Central Texas Clinical Research
Austin, Texas, United States
Peter Shalit, M.D.
Seattle, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Emtricitabine →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Jan 2011
Primary completion: 31 Jul 2011
Completion: 31 Mar 2012
Last update posted: 26 Apr 2013
Registered enrollment: 50
Registry id: NCT01286740

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.